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pregnancy outcomes. Methods: To determine whether additional clinical tests, 
advice, planning, management or pregnancy follow-up were recommended for 
obese women during pregnancy,Clinical Practice Guidelines (CPGs) were collated 
from across the Endocrinology and Obstetrics National Societies websites of 
the 9 European countries participating in the FP7 DALI study (Austria, Belgium, 
Denmark, Ireland, Italy, The Netherlands, Poland, Spain, UK). This was comple-
mented by a Medline search and a survey among the investigators of the DALI 
study. Results: Fifteen CPG for 9 countries were retrieved. All but Spanish guide-
lines, which recommend O’Sullivan test, recommend OGTT 75g to detect GDM in 
obese women. Most of them include 24-28 weeks as the time for OGTT, but other 
schedules are also used, especially when risk factors other than obesity are pre-
sent. Other common recommendations for obese women in European CPGs were 
diet advice (included in the guidelines of 6 different countries), special birth plan-
ning (5 countries), exercise and other lifestyle recommendations (4 countries) and 
vitamin D supplementation, multidisciplinary follow-up (including endocrinolo-
gist or diabetologist) and additional ultrasound scan (3 countries). ConClusions: 
Recommendations for obese women in the studied countries are heterogeneous 
and in many cases do not include actions beyond screening for GDM. Existing 
guidelines will be reviewed in the light of the findings from the interventions 
studied in the framework of the DALI study.
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objeCtives: Infertility affects 14% of couples in reproductive age in Spain. 
Progressive population ageing leads the assessment of policies that favor birth-
rates. The objective is estimating the lifetime economic benefits of publicly 
financing assisted reproductive therapies (ART) in Spain, by calculating the 
return on this investment. Methods: Generational accounting model that 
simulates the flow of taxes paid by the individual minus those direct govern-
ment transfers received (e.g. health care, education, pensions) over the lifecycle 
of a child. The cost of ART was calculated as the average cost of conceiving a 
child through currently available ART in Spain. The difference between dis-
counted transfers and taxes minus the cost of ART equals the net present value 
(NPV) of a child conceived by ART. Year 2006 was set as the base case because 
of its macroeconomic stability. A 3.5% discount rate was applied. Sensitivity 
analysis tested robustness of results under different scenarios. Results: An 
ART-conceived child would contribute € 534,624 in net taxes to the government 
and would receive € 479,952 in governmental transfers over her lifecycle. After 
discounting the cost of ART (9,000€ ) the NPV is estimated at € 45,672. Each Euro 
invested in subsidizing ART reverts into fiscal benefits of € 5. Sensitivity analy-
sis shows that even in extreme macroeconomic scenarios, the long-run NPV 
of an ART-conceived child ranges between € 11,233 and € 62,470. The return on 
investment varies between € 1.25 y € 6.94 € for each Euro invested in ART. The 
break-even age at which the financial position begins to be favorable to the 
Spanish Treasury was set at 34-42 years. ConClusions: Generational account-
ing models allow estimating long-term fiscal implications of public funding of 
ART. Each Euro invested in subsidizing ART reverts into fiscal benefits of € 5. 
Thus, investment in ART leads to substantial discounted future fiscal revenue 
for the Spanish Treasury, notwithstanding its beneficial psychological effect 
for infertile couples.
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objeCtives: The new German law AMNOG was introduced in 2011. According to 
it all newly launched therapy options would need to be evaluated by the Institute 
for Quality and Efficiency in health care (IQWIG) and the joint federal committee 
(Gemeinsamer Bundesausschuss, GBA) before a final price negotiation will happen. 
Given the specific characteristics of pediatric patients it is uncertain if a new drug 
for those patients would successfully pass the AMNOG process. Methods: The 
AMNOG evaluation criteria were applied to the specifics of pediatric drugs. A special 
focus was given to the benefit assessment method, clinical trial designs and the 
AMNOG process. Results: Current HTA evaluation methods being applied to medi-
cal therapies, in general, need to be modified when applied to pediatric therapies. 
For example, traditional benefit evaluations that require randomized clinical trials 
are standard but cannot always be fulfilled in this patient population. In pediatric 
development programs one-arm studies are standard with surrogate endpoints in 
order to minimize the exposure of children to an experimental therapy. Additionally 
the naturally low sample size within pediatric indications linked to the different 
natural subgroups of children (babys, toddlers, etc.) make a formal additional ben-
efit proof even harder. Hence from a benefit assessment perspective the clinical 
study design, sample size and choice of endpoint are most crucial but could hardly 
be executed in pediatric trials. With respect to the AMNOG process only pediatric 
trials in orphan disease could pass successfully given the exception rules for the 
additional benefit. ConClusions: If the German health care system is to secure 
the full benefits of potential new pediatric therapies, it will need to provide a similar 
process as it is granted for orphan drugs.
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an acute condition (acute tonsillitis in an 8 year old child) and a chronic condition 
(an adult with diabetes mellitus type 2) was developed. WTP for a BD as compared 
with a GD was assessed in both scenarios using the payment scale and the open-
ended formats. The study was approved by the local ethical committee. Results: 
Respondents were predominantly women (57%) and the mean age was 54 y.o. A 
family income of less than R$ 1.356,00 was reported by 16%. For the total study 
sample, the maximum WTP for a BD (over and above the mean retail price of a GD) 
for the acute and chronic case scenarios were on average R$ 27,54 and R$ 21,04 
when measured by the payment scale and R$ 36,54 and R$ 24,77 when measured 
by the open-ended question, respectively. These values are 36% to 65% above the 
mean retail prices of the corresponding GD. ConClusions: Patients and accom-
panying persons were willing to pay considerably more for the BD when compared 
to GD. This may be driven by the perception of higher perceived effectiveness and 
safety of BD.
IndIvIduaL’s HeaLTH – Health care use & Policy studies
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objeCtives: To assess which of the studied factors were positively associated with 
the students’ health and to investigate which of these factors stood out as the most 
important protective factors for their health. Methods: Data were obtained from 
a cross-sectional study conducted during the academic 2011/2012th at the universi-
ties in Niš, Belgrade and Novi Sad, which surveyed a total of 2285 students of both 
sexes. This study examines variables such as physical, psychological and social 
health, protective factors and risk factors. Students were assessing their own health 
answering the questionnaire. Results: Only 11.8% of the surveyed students have 
assessed their health as excellent, 72.5% as very good or good, and 15.7% as poor or 
very poor. Better health status was positively correlated with the quality of sleep, 
the existence of free time, physical and social activities, religiosity and built health 
values in all three universities. Kruskal-Wallis H test showed that better students are 
more satisfied with their life (p < 0.001), that better assess their health (p < 0.01) and 
less drink alcoholic beverages. Female students had more physical pain, were more 
frequently depressed than men, they were more easily tired, they were much more 
nervous and had more problems than men with sleep. Men assessed their health as 
better than female students. However, the satisfaction scale (χ 2 homogeneity test; 
p < 0.001) were found females to be more satisfied with their lives than male stu-
dents. ConClusions: General health is affected by various physical, psychological 
and social aspects of health. The results show that there are significant protective 
factors for better social, psychological and general health in students that may be 
affected. Therefore, health promotion decision makers should adopt contemporary 
strategies that will in the future put emphasis on the social and psychological 
components of students’ health.
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objeCtives: Uterine fibroids (UF) affect approximately 20% to 40% of repro-
ductive-aged women. The mainstay of treatment of symptomatic UF is surgical. 
Myomectomy surgically removes UF while preserving the uterus. However, hyster-
ectomy that is considered to be the definitive treatment of UF, causes infertility.The 
aim of our study was to analyze the prevalence of hysterectomy in Hungary among 
reproductive-aged women with UF to assess the societal burden due to lost fertil-
ity. Methods: Database were analyzed. Surgical procedures for the treatment of 
UF (ICD-10: D25), in 20-45 years old women between 2007 and 2012 were analyzed 
based on the Hungarian National Health Insurance Fund database. Economic bur-
den of lost fertility was assessed by the human capital approach. Present value of 
life for a newborn child was calculated by applying 2011 GDP per capita and 3.7% 
discount rate. Results: Among 11,095 women with surgical procedure related 
to UF the prevalence of hysterectomy was 61.5% (n= 6827). Most hysterectomised 
women (n= 4781) were 40-45 years old; unexpectedly a significant number of 20-40 
years old women with UF had hysterectomy (n= 2046). Present value of a newborn 
child was 262,314 EUR in 2011. ConClusions: Our results indicate that immediate 
hysterectomy, even in women under 40 years, is still a frequently performed surgi-
cal procedure for the treatment of UF. The macroeconomic consequences of lost 
fertility due to hysterectomy in reproductive-aged women with UF are significant. 
Even only one additional child-birth due to avoided hysterectomy would result in 
significant societal and economic benefits. Further scientific evaluations are needed 
to define more accurately the long term macroeconomic impact of preserved fertil-
ity in women with UF.
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objeCtives: To review, within the framework of the FP7 DALI (Vitamin D And 
Lifestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention) study, 
guidelines for the management of obese women during pregnancy across Europe 
to assess the specificity of the recommendations in this group at risk of adverse 
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specific. Except for preschoolers, therapeutic management of patients with ADHD 
relied heavily on drug treatment.
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objeCtives: To measure the change in the risk of first, second, and third hospitali-
zation and the change in the proportion of hospitalization-free men and women 
above the age of 60 living in Stockholm and Uppsala counties in Sweden between 
1972 and 2010. Methods: Individuals were followed in national registers for hos-
pitalizations and deaths from all causes between 1972 and 2010. Censoring occured 
at whichever of the following events appeared first; hospitalization (first, second, 
thrid), death, or December 31, 2010. Survival analysis was used to determine the 
proportion of hospitalization-free individuals. Discrete time logistic regression 
was used to obtain the the relative risk (RR) of first, second and third hospitaliza-
tion. Results: An increase in the proportion of hospitalization-free individuals over 
time was observed for both men and women; for example 87% more 82 year-old 
men, born in 1928, were free of hospitalizations since the age of 60 compared to 
those born in 1912. Between the years 1972 and 2010, the average annual decrease 
in the risk of first hospitalization after the age of 60 was 1% for both men (RR: 
0.991, 95%CI: 0.991-0.992) and women. The average annual risk for hospitalization 
decreased for the second and thrid event as well; however the reduction was not 
significant. ConClusions: With the increase in the proportion of elderly in the 
population, the number of individuals with chronic diseases may increase, leading 
to higher demand for medical and social care. We have observed downward trends of 
the risk of first, second, and third hospitalization after the age of 60, which could be 
explained by a postponement of severe morbidity to higher ages. Focus on primary 
care and changes in inpatient care in Sweden may also partly exaplain the annual 
reduction in the risk of hospitalization.
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objeCtives: Since the implementation of Pediatric Regulations/Legislations in the 
USA (Pediatric Research Equity Act - PREA) and in Europe (Pediatric Investigation 
Plans - PIPs), product development programs should include pediatric studies. The 
objective of this study is to review opinions (EMA) and requirements (FDA) given by 
both agencies in the case of sitagliptin (alone and combined) for the treatment of 
diabetes mellitus in children. Methods: The EMA and FDA websites were explored 
to: 1) Identify the products marketed under the INN of sitagliptin (alone or in com-
bination), and 2) Identify the associated PIPs or PREA requirements. The search was 
performed on January 18, 2013. Results: Eight products were marketed in Europe 
[i.e., sitagliptin (Januvia, Ristaben, Tesavel, Xelvia) and sitagliptin + metformin 
(Janumet, Efficib, Ristfor, Velmetia)]. Four products were authorized in the USA [i.e., 
sitagliptin (Januvia); sitagliptin + metformin (Janumet, Janumet XR); sitagliptin + 
simvastatin (Juvisync)]. The FDA and the EMA provided the same opinion for sitag-
liptin alone, i.e., deferred pediatric study for patients aged 11 to 16. The FDA and the 
EMA disagreed on sitagliptin + metformin. The EMA granted a waiver for all subsets 
of the pediatric population on the grounds that the specific medicinal product does 
not represent a significant therapeutic benefit over existing treatments, while the 
FDA required a pediatric study under PREA for the treatment of type 2 diabetes in 
pediatric patients aged 11 to 16. As for sitagliptin + simvastatin, the FDA grants a 
waiver on the grounds that the product does not represent a meaningful therapeutic 
benefit over existing therapies for pediatric patients. ConClusions: The FDA and 
the EMA have similar opinions except for the combination sitagliptin + metformin. 
One reason could be the higher prevalence of type 2 diabetes mellitus in children 
in the USA as compared to Europe.
InFecTIon – clinical outcomes studies
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objeCtives: The objective of the present study was to assess the geographic cor-
relation between the incidence of Lyme disease (LD) and mortality due to certain 
degenerative neurologic diseases (DND) in the US. Methods: For this ecological 
study, public data sources at the CDC were queried to quantify LD cases and DND 
deaths for the 5-year period 2002-2006. Alzheimer’s disease, Parkinson’s disease, 
and motor neuron disease were preselected as DND of interest. The separate 
datasets, for LD and DND, were combined by matching county and state names. 
Counties with at least 1 case of LD and at least 10 deaths due to DND were included 
in analyses. All analyses were performed in SAS. Results: Of the 3141 counties of 
the US, 1372 reported at least 1 case of LD, 2742 reported at least 10 deaths due to 
DND, and 1339 met both conditions and were therefore included in analyses. The 
observed number of LD cases and DND deaths for a single county ranged from 1- 
6407 (mean: 78; median: 3) and 10-9207 (mean: 165; median: 55), respectively. The 
Spearman rank test indicated that there is a fair degree of correlation between LD 
incidence and DND mortality (r= 0.44, p< 0.0001). In sensitivity analyses, (1) exclud-
ing outliers, defined as observations ≥ 99th percentile (LD> 53; DND> 1255), and (2) 
evaluating each disease separately, the correlation remained similar in magni-
tude and statistically significant (coefficient: 0.32-0.41; p< 0.0001). ConClusions: 
There is a fair degree of correlation between LD incidence and DND mortality: 
US counties with a higher number of LD cases tend to have a higher number of 
objeCtives: Anabolic-Androgenic Steroids (AAS) have been used for muscle mass 
development for over fifty years. The health outcomes of supraphysiologic doses of 
AAS have been debated, but most existing information pertains to men. This pur-
pose of the study is to use the National Longitudinal Study of Adolescent Health 
(AddHealth) to elucidate health outcomes of AAS usage in women. Methods: 
A cohort study of female AAS users were assessed in two time periods six years 
apart. Baseline descriptive statistics were used to describe age, income, race, drug 
use, education, and work performed for the sample. Follow up health outcomes 
include diabetes, heart disease, hyperlipidemia, anger, physician visit, use of medi-
cal care in the last year, Body Mass Index (BMI), blood pressure (BP), C-reactive 
protein, and HbA1C. Each dependent variable was tested in independent logis-
tic regressions and in sensitivity tests using a MANOVA. Results: The sample 
included 49 female respondents. Education was associated with a two-fold greater 
odds of AAS use comparing those who attended vocational school to those who 
attended college (OR= 2.22, p= .03). Anger was associated with 88% greater risk of 
AAS use (OR= 1.88, p= .04). HbA1c in the pre-diabetic range, while not statistically 
significant may be associated with AAS use (OR= 1.85, p= .05). No other health 
outcomes were identified. ConClusions: This study contributes to the literature 
of female AAS use showing little in health care usage and long term health conse-
quences. Anger is associated with male users but little research exists pertaining 
to this phenomenon in women. Elevated HbA1c is not commonly associated with 
AAS use, but due to the small sample size more research should assess AAS use 
among females.
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objeCtives: As a basis for future safety evaluations of oral contraceptive (OC) use in 
Europe, current user and treatment characteristics were assessed in four European 
health care databases. Methods: A descriptive retrospective database study was 
performed over 2009-2010 in GP databases from The Netherlands (IPCI), UK (THIN) 
and Italy (HSD) and linked pharmacy dispensing and hospital admission data from 
The Netherlands (PHARMO). Study follow-up started at the first OC prescription 
in 2009-2010 (users), one year after database entry or at Jan 1, 2009. Health indica-
tors at start of follow-up included BMI and previous diagnosis of, or use of drugs 
for selected chronic conditions. Also, previous diagnoses of deep vein thrombosis, 
pulmonary embolism, cerebrovascular disease, myocardial infarction, breast cancer 
and cervical cancer were assessed. Treatment characteristics of OC included his-
tory of use, type of OC (chemical substance) used during 2009-2010 and switches or 
discontinuations. Results: Among 4.9 million women, 14% had OC prescribed in 
2009-2010. In The Netherlands and UK, 12-16% and in Italy 6% had a record of OC 
use. The prevalence of OC recorded prescription at January 1, 2010 was 81 per 1000 
women of all ages and 271 per 1000 women aged 15-24, a much lower figure than 
what is recorded by surveys, probably due to switches between use and non-use 
and to reimbursement and/or prescription policies that reduce recording in GP data-
bases. Among the non-users in 2009-2010, up to 22% had a history of OC recorded 
use. Little differences in health indicators were found between users and non-users 
in the databases where the information was available. ConClusions: Trends in 
health among European women in general also apply to OC users. However, OC use 
is not registered very well in health care databases which limits the possibilities 
of pharmacovigilance. Distribution channels and reimbursement policies vary, as 
well as recording in the databases.
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objeCtives: To explore health care utilization and treatment patterns for atten-
tion-deficit/hyperactivity disorder (ADHD) in Germany, with particular emphasis 
on psychostimulant prescriptions. Methods: The complete claims database of 
the organization of physicians registered with statutory health insurance (SHI) 
in Nordbaden/Germany was available for analysis, covering the total regional 
population enrolled in SHI (2.24 million lives). The dataset for years 2003 to 2009 
was reorganized as to allow patient-centered evaluation. For calendar year 2009, 
21,287 patients with ADHD (male, 15,108; female, 6,179; including 5,931 patients 
or 27.9% [male, 4,582; female, 1,349] with coexisting conduct disorder [F90.1 or a 
combination of F90 and F91 codes according to ICD-10]) were available for anal-
ysis. Results: Preschool children (age 0-5 years) with ADHD were prescribed 
medication in very rare cases (1.6% in 2009) and after an average lead time of 
more than one year only. Most received some form of nonpharmacological therapy 
or were left untreated (42%). In contrast, 41% of children (age group 6-12 years, 
since 2003, continuously increasing from 32%) and 54% of adolescents (age group 
13-17 years, rate remaining stable since 2006) were prescribed either stimulant 
(methylphenidate, MPH, or amphetamine) or nonstimulant (atomoxetine) drugs. 
Males and patients with concomitant conduct disorder were more likely to receive 
medication treatment. Modified-release MPH formulations were more widely used 
than immediate-release MPH. Overall use of medication increased steadily, from 
32.2% of ADHD patients in 2003 to 39.9% in 2009, whereas its rate decreased over 
time in adult patients (declining from 38% in 2003 to 26% in 2009). – Upon indi-
vidual review of all prescriptions of ADHD medication for members of the control 
group, no evidence was found supporting potentially inappropriate use of stimu-
lant medication. ConClusions: Treatment patterns were highly age and gender 
